Faculty profile

Nadeem Moghal

ResearcherResearch InstituteUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Nadeem Moghal

Researcher

Research Institute

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2025.
Principal investigator on 2 research grants (2 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Lung Cancer Proteomics Sox2 Cell Biology Crispr Functional Genomics Mouse Organoids

Latest papers

Distal tip cell migration mutants of Caenorhabditis elegans are rescued by bioequivalent outputs from chondroitin and N-glycosylation pathways.
The Journal of biological chemistry · 2025
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023 · first author
The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
Cancer medicine · 2023

All 20 publications

Latest funding

Identification of novel therapeutic targets for SOX2-driven lung squamous cell carcinoma
CIHR · 2020 · Nominated PI
$650,252
Study of SOX2-mediated oncogenesis in lung squamous cell carcinoma
CIHR · 2014 · Principal investigator
$100,000

All 2 grants and awards

20 publications.

Distal tip cell migration mutants of Caenorhabditis elegans are rescued by bioequivalent outputs from chondroitin and N-glycosylation pathways.

Dennis JW, Dunn RJ, Levy-Strumpf N, Brooun M, Moghal N, Culotti JG

The Journal of biological chemistry2025

DOI: 10.1016/j.jbc.2025.110895 PMID: 41197717

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.

Moghal N, Li Q, Stewart EL, Navab R, Mikubo M, D'Arcangelo E, Martins-Filho SN, Raghavan V, Pham NA, Li M, Shepherd FA, Liu G, Tsao MS

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023First author

DOI: 10.1016/j.jtho.2022.12.003 PMID: 36535627

The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.

Ji L, Moghal N, Zou X, Fang Y, Hu S, Wang Y, Tsao MS

Cancer medicine2023

DOI: 10.1002/cam4.5311 PMID: 36305267

Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.

Mirhadi S, Tam S, Li Q, Moghal N, Pham NA, Tong J, Golbourn BJ, Krieger JR, Taylor P, Li M, Weiss J, Martins-Filho SN, Raghavan V, Mamatjan Y, Khan AA, Cabanero M, Sakashita S, Huo K, Agnihotri S, Ishizawa K, Waddell TK, Zadeh G, Yasufuku K, Liu G, Shepherd FA, Moran MF, Tsao MS

Nature communications2022

DOI: 10.1038/s41467-022-29444-9 PMID: 35383171

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors.

Huo KG, Notsuda H, Fang Z, Liu NF, Gebregiworgis T, Li Q, Pham NA, Li M, Liu N, Shepherd FA, Marshall CB, Ikura M, Moghal N, Tsao MS

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022

DOI: 10.1016/j.jtho.2021.09.008 PMID: 34648945

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.

Rosen JC, Weiss J, Pham NA, Li Q, Martins-Filho SN, Wang Y, Tsao MS, Moghal N

Translational oncology2021Senior author

DOI: 10.1016/j.tranon.2021.101179 PMID: 34284202

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G

Lung cancer (Amsterdam, Netherlands)2020

DOI: 10.1016/j.lungcan.2020.05.018 PMID: 32521388

Sensory regulated Wnt production from neurons helps make organ development robust to environmental changes in C. elegans.

Modzelewska K, Brown L, Culotti J, Moghal N

Development (Cambridge, England)2020Senior author

DOI: 10.1242/dev.186080 PMID: 32586974

EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.

Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G

Lung cancer (Amsterdam, Netherlands)2020

DOI: 10.1016/j.lungcan.2020.03.022 PMID: 32447118

Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane.

Fang Z, Lee KY, Huo KG, Gasmi-Seabrook G, Zheng L, Moghal N, Tsao MS, Ikura M, Marshall CB

Proceedings of the National Academy of Sciences of the United States of America2020

DOI: 10.1073/pnas.1914076117 PMID: 32414921

Something wrong or missing on this profile? Suggest a correction

Nadeem Moghal

Research

Latest papers

Latest funding

Distal tip cell migration mutants of Caenorhabditis elegans are rescued by bioequivalent outputs from chondroitin and N-glycosylation pathways.

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.

The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.

Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors.

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

Sensory regulated Wnt production from neurons helps make organ development robust to environmental changes in C. elegans.

EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.

Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane.

Identification of novel therapeutic targets for SOX2-driven lung squamous cell carcinoma

Study of SOX2-mediated oncogenesis in lung squamous cell carcinoma

Frequent collaborators

Ming-Sound Tsao

Geoffrey Liu

Kazuhiro Yasufuku

Mitsuhiko Ikura

Benjamin Haibe-Kains

Joseph Culotti

Adrian Sacher

Laurie Ailles

Shaf Keshavjee

Gelareh Zadeh

Brian Raught

Thomas Kislinger

Igor Jurisica